Patients' risk of hospitalization or all-cause mortality decreased 87% with a three-day course of intravenous remdesivir, according to data released by Gilead. Remdesivir is approved for use in hospitalized patients, but outpatient treatment for high-risk individuals like those included in the study is investigational.
Designed specifically for the transfusion medicine and cellular therapy community, AABB SmartBrief is a FREE, daily e-mail newsletter. It provides a summary of the most important news in our field to members of AABB and beyond. To save time and stay smart, sign up today to receive AABB SmartBrief, free of charge.